BIOT was named by CelSiege Biosciences as its non-exclusive authorized introduction and business development representative in Japan and China for IN01, a clinical-stage cancer immunotherapy. Under a Letter of Authorisation signed September 18, 2026, BIOT may introduce the program to prospective partners and investors and facilitate preliminary discussions about potential investment, licensing, co-development, clinical development, manufacturing and commercialization. Any definitive transaction remains subject to separate negotiations, due diligence and definitive agreements.
CelSiege describes IN01 as an active immunotherapy, or therapeutic cancer vaccine, targeting epidermal growth factor. Development materials identify squamous non-small cell lung cancer as the lead indication. IN01 has not received marketing approval.
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (BIOT) reports that Nasdaq has notified it of three separate deficiencies with continued listing standards for the Nasdaq Global Market. Nasdaq found that from July 28, 2026 to September 8, 2026 the Company’s market value of listed securities (MVLS) was below US$50,000,000, and from July 29, 2026 to September 9, 2026 the market value of publicly held shares (MVPHS) was below US$15,000,000, breaching Listing Rules 5450(b)(2)(A), 5450(b)(3)(A), 5450(b)(2)(C) and 5450(b)(3)(C).
Nasdaq also determined that the Company’s ordinary share minimum bid price was below US$1.00 during the July 29, 2026 to September 9, 2026 period, violating Listing Rule 5450(a)(1). Each notice currently has no immediate effect on trading, but BIOT has 180 calendar days to regain compliance for MVLS (until March 8, 2027) and for MVPHS and bid price (until March 9, 2027). If compliance is not restored, Nasdaq may initiate delisting, though Instinct Bio could appeal or seek transfer to the Nasdaq Capital Market. The Company states it is evaluating options and notes there is no guarantee it will regain or maintain compliance.
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (BIOT) reports an operational update on its GENRÊVER CLINIC platform in Indonesia and product development collaborations with Invitrx Therapeutics, Inc. and PT Parva Candela. Management states that site development activities in Jakarta are progressing and product planning discussions with manufacturing collaborators in the United States and Indonesia are ongoing.
The update reiterates that expectations for clinic opening and operations, subscription offerings, product development, manufacturing timelines, and collaborations are forward-looking statements subject to risks such as construction delays, regulatory developments, development outcomes, supply chain constraints, market conditions, negotiation of definitive agreements, and customer acceptance, as well as other risks described in the company’s SEC filings.
Instinct Bio Technical Company Holdings Inc. reported that it has entered into a cooperation agreement with PT Parva Candela, an Indonesian cosmetics manufacturer and distributor, to jointly develop Indonesia’s cosmetics and personal care market under a “Made in Indonesia, Powered by Japanese Formulation Expertise” concept. The collaboration is positioned as part of Instinct Bio’s broader strategy, which includes Japan-originated businesses in regenerative medicine R&D, sourcing, manufacturing, cosmetics, wellness and consumer brands. The company states there can be no assurance the collaboration will achieve specific commercial results or that a joint venture company will be formed, highlighting execution and market risks for this initiative.